1. Market Research
  2. > Biotechnology Market Trends
  3. > Competitor Analysis c-Met/HGF Inhibitors

Competitor Analysis c-Met/HGF Inhibitors

  • February 2010
  • -
  • La Merie Publishing

Product description

The Competitive Intelligence Report c-MET/HGF Inhibitors as of February 2010 provides a competitor analysis in the development pipeline of novel emerging inhibitors of c-MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor (HGF) or scatter factor (SF) for treatment of solid tumors. Most of the inhibitors are small molecules, but antibodies are a strongly emerging class of c-Met/HGF antagonists.

The c-MET signalling pathway consists of the mesenchymal epithelial transition factor (c-MET) transmembrane tyrosine kinase receptor and its ligand hepatocyte growth factor (HGF) or scatter factor (SF). Binding of HGF/SF to c-MET activates downstream signalling pathways such as Rho, focal adhesion kinase (FAK) and PI3K. These pathways regulate cancer cell growth, survival angiogenesis, invasion and metastasis. Thus, prevention of c-MET dependent neoplastic processes may provide a means for managing invasive tumors of high metastatic potential. In fact, c-MET/HGF has evolved as an attractive target for the pharmaceutical industry.

At present, at least 16 different molecules including four antibodies are in clinical development and quite a number of projects are in preclinical development. The majority of approaches are directed at inhibiting the c-MET receptor tyrosine kinsase (RTK) by small molecules. The first generation of c-MET RTK inhibitors are dual- or multi-targeting c-MET inhibitors. These multi-target c-MET inhibitors are most advanced in clinical development with two projects in phase III. The next wave of c-MET inhibitors typically are ATP-competitive potent and highly selective c-MET inhibitors with lead compounds in phase II.

The Competitor Analysis c-MET/HGF Inhibitors also provides the corporate R&D pipelines for c-MET/HGF Inhibitors. The report includes a compilation of current active projects in research and development of c-Met/HGF Inhibitors. Competitor projects are listed in a tabular format providing Information on:

* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Product category,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.

Index

* Selective c-MET/HGF Inhibitors
* Dual- and Multi-Targeting c-MET/HGF Inhibitors
* C-Met/HGF Inhibitory Antibodies

Table Of Contents

Competitor Analysis c-Met/HGF Inhibitors

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

ASIA-PACIFIC (5 Countries) MARKETS FOR DENTAL BONE GRAFT SUBSTITUTES AND BARRIER MEMBRANES - 2011-2021

ASIA-PACIFIC (5 Countries) MARKETS FOR DENTAL BONE GRAFT SUBSTITUTES AND BARRIER MEMBRANES - 2011-2021

  • $ 7 495
  • Industry report
  • April 2015
  • by iData Research, Inc.

The loss of bone can cause discomfort and prevent patients from receiving dental implants. Bone grafting procedures using bone graft substitutes (BGS) are performed to repair bone loss. Bone grafting can ...

Regenerative Medicines: Bone and Joint Applications

Regenerative Medicines: Bone and Joint Applications

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research report focuses on the bone- and joint-related applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced ...

Single-Use Technologies for Biopharmaceuticals: Global Markets

Single-Use Technologies for Biopharmaceuticals: Global Markets

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research report analyzes the single use technology industry structure with revenues projected for the five-year period from 2014 through 2019. Use this report to: - Learn about present and future ...

Us Enzymes Market, Freedonia

May 2015 $ 5 300

Download Unlimited Documents from Trusted Public Sources

Influenza Vaccine Statistics in the US

  • June 2015
  • Influenza Vacci...  

    Vaccine  

  • United States  

    North America  

View report >

Vaccine Statistics in the UK, Quarterly Update

  • June 2015
    13 pages
  • Vaccine  

    Hepatitis B  

  • United Kingdom  

    Europe  

View report >

Oncology Industry in the US - Forecast

  • June 2015
    6 pages
  • Oncology  

    Cancer Therapy  

    Cancer  

  • United States  

View report >

Pear Industry In Iran

14 days ago

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.